Enhance your nephrology practice with CME and tools focused on kidney medicine.
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
June 05, 2026
Glasgow
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Quantifying CKD-aP: Tools for Better Care
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
Leonie Kraft, MD
Lucio Manenti, MD, PhD
The Patient-Clinician Connection in Managing CKD-aP
Is CKD-aP Hiding in Your Dialysis Center?
Elevating CKD-aP Care: New Frontier
Advancing Patient-Centered, Guideline-Driven Management of Hyperkalemia in Adults With CKD and Associated Comorbidities
June 04, 2026
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Kappa-Opioid Settings: Real-World Evidence Insights
The Critical Interplay: CKD, HF, and HyperkaleAmia
Javed Butler, MD
Patrick Rossignol, MD, PhD
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Javed Butler, MD, MPH, MBA
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Potassium Binders: Safety Comes First!
Future Directions in Managing Hyperkalemia in CKD and HF
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Sydney Tang, MBBS, MD
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC
Piotr Ponikowski, MD, PhD, FESC, FHFA
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
Incorporating Targeted Therapies in Treatment Planning for AAV
David Jayne, MD
Bernhard Hellmich, MD
Can We Do Better in IgAN?
Annette Bruchfeld, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.